Sugi Predict

Sugi Predict / Compounds / SCHEMBL458005

SCHEMBL458005

SCHEMBL458005

O=C(O)c1ccc(OCC(F)(F)F)nn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ POLB P06746 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ EPHX2 P34913 3/20 0.40
▸ MAPT P10636 3/20 0.39
▸ IL1B P01584 1/20 0.39
▸ NNMT P40261 1/20 0.39
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CYP2J2 P51589 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ SCN9A Q15858 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ S1PR2 O95136 1/20 0.36
▸ S1PR4 O95977 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ XBP1 P17861 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15350224 0.87 L3MBTL1 (0.44) L3MBTL1SMN1; SMN2POLBMAPK1IL1B
SCHEMBL15350505 0.84 L3MBTL1 (0.42) L3MBTL1SMN1; SMN2POLBMAPK1MAPT
SCHEMBL15350216 0.83 L3MBTL1 (0.47) L3MBTL1SMN1; SMN2POLBMAPK1EPHX2
SCHEMBL24124568 0.78 MAPT (0.53) L3MBTL1SMN1; SMN2POLBMAPK1EPHX2
SCHEMBL30342225 0.78 L3MBTL1 (0.43) L3MBTL1SMN1; SMN2POLBMAPK1MAPT
SCHEMBL29005252 0.78 L3MBTL1 (0.43) L3MBTL1SMN1; SMN2POLBMAPK1MAPT
SCHEMBL1403622 0.77 MAPT (0.54) L3MBTL1MAPK1MAPTNNMTALDH1A1
SCHEMBL795791 0.75 L3MBTL1 (0.53) L3MBTL1POLBMAPK1EPHX2MAPT
SCHEMBL30281209 0.75 L3MBTL1 (0.53) L3MBTL1POLBMAPK1EPHX2MAPT
SCHEMBL31133136 0.75 L3MBTL1 (0.59) L3MBTL1POLBMAPK1EPHX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516046-B2 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2026-01-06 — — US disclosed
US-11802122-B2 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2023-10-31 — — US disclosed
US-20230312528-A1 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-10-05 — — US disclosed
US-20230227441-A1 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-20 — — US disclosed
CN-116134018-A 2-oxoimidazolidine-4-carboxamide as NAV1.8 inhibitor 默沙东有限责任公司 2023-05-16 — — CN disclosed
CN-116056697-A 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors 默沙东有限责任公司 2023-05-02 — — CN disclosed
EP-4167994-A1 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-04-26 — — EP disclosed
EP-4168393-A1 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-04-26 — — EP disclosed
US-20210403457-A1 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-12-30 — — US disclosed
WO-2021257490-A1 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — WO disclosed
WO-2021257418-A1 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — WO disclosed
EP-2841421-B1 AMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2019-06-05 — — EP disclosed
US-9701658-B2 Amide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2017-07-11 — — US disclosed
US-9701658-B2 Amide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2017-07-11 — — US disclosed
US-9701658-B2 Amide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2017-07-11 — — US disclosed
US-20150105393-A1 AMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2015-04-16 — — US disclosed
US-20150105393-A1 AMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2015-04-16 — — US disclosed
US-20150105393-A1 AMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2015-04-16 — — US disclosed
EP-2841421-A1 AMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2015-03-04 — — EP disclosed
WO-2013161308-A1 AMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2013-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403457-A1 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS SCN8A, TRPV1, SCN2A L3MBTL1 3932/4885SMN1; SMN2 502/4885POLB 4715/4885
US-20150105393-A1 AMIDE DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN5A, SCN1A L3MBTL1 1939/4885SMN1; SMN2 528/4885POLB 3684/4885
US-20230227441-A1 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS SCN8A, TRPV1, SCN2A L3MBTL1 3564/4885SMN1; SMN2 448/4885POLB 4584/4885
US-11802122-B2 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors SCN8A, TRPV1, SCN2A L3MBTL1 3932/4885SMN1; SMN2 502/4885POLB 4715/4885
US-20230312528-A1 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS SCN8A, TRPV1, SCN2A L3MBTL1 4018/4885SMN1; SMN2 440/4885POLB 4736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.